Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies that are patient, physician, caregiver, and societal friendly. Its lead development candidate is ivonescimab, a bispecific antibody designed for immunotherapy through blockade of PD-1 combined with anti-angiogenesis. This candidate is being developed for the treatment of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy in a phase III clinical trial for patients with epidermal growth factor receptor (EGFR) mutated, locally advanced or metastatic non-squamous NSCLC. Additionally, its portfolio includes first-line metastatic NSCLC and first-line unresectable metastatic CRC indications.

Summit Therapeutics Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol SMMT. The company trades in US dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange. The NasdaqGM is a tier of the Nasdaq stock exchange that includes companies meeting certain financial and liquidity requirements. Investors can buy and sell shares of Summit Therapeutics through brokerage accounts that have access to US markets.

Summit Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on discovering and developing novel therapies for serious diseases, particularly in oncology. The biotechnology industry involves using biological processes and organisms to create medical treatments, and Summit's work with bispecific antibodies and immunotherapies places it squarely in this innovative field. The company's lead candidate, ivonescimab, exemplifies its focus on cutting-edge cancer treatments that combine immune checkpoint inhibition with anti-angiogenic effects.

Summit Therapeutics Inc. is headquartered in Miami, Florida, United States. The company was founded in 2003 and markets its products in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. This broad geographic reach indicates that Summit aims to commercialize its therapies globally, though its lead candidate ivonescimab is still in clinical development. The company's focus on patient-friendly therapies suggests it targets markets with advanced healthcare systems and significant unmet medical needs in oncology, particularly for non-small cell lung cancer and colorectal cancer.

Summit Therapeutics Inc. generates value by discovering, developing, and commercializing innovative biopharmaceutical therapies. Its business model centers on advancing its lead candidate, ivonescimab, a bispecific antibody that blocks PD-1 and inhibits angiogenesis, through clinical trials and ultimately to market. The company is currently conducting a phase III clinical trial combining ivonescimab with chemotherapy for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. Additionally, its pipeline includes first-line metastatic NSCLC and first-line unresectable metastatic CRC indications. Revenue would come from product sales and potentially licensing agreements, though the company is pre-commercial and has not yet generated product revenue from its pipeline.